Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...
Investor's Business Daily on MSN
Sarepta Loses Almost A Third Of Its Value On Failed Tests, Gene Therapy Outlook
Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.
A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.
Despite disruptions and restructuring costs, Sarepta Therapeutics Inc (SRPT) showcases strong revenue performance and ...
Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...
Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...
Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...
Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...
Sarepta Therapeutics Inc. shares plunged after a trial designed to confirm the benefits of two of its older drugs failed to show clear patient improvement, raising questions about their future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback